Introduction {#s1}
============

The application of high-throughput genomic techniques makes it possible to identify variation across the genome that may help to predict clinical response to drug treatment [@pone.0007765-Sachidanandam1]--[@pone.0007765-Morley1]. Wide variations in response to many antineoplastic drugs exist in the clinic. Therefore, it is crucial to identify biomarkers that will help make it possible to maximizing efficacy while minimize drug-related toxicity. One possible explanation for variation in response to chemotherapy is genetic variation that influences gene expression and, ultimately, impacts variation in drug response phenotypes [@pone.0007765-Weidinger1]--[@pone.0007765-Bergman1]. Most previous studies have focused on biomarkers in tumor tissue and their relationship with therapeutic response [@pone.0007765-Gwee1]--[@pone.0007765-Gullans1]. While identifying genetic biomarkers in the tumor is important for understanding tumorigenesis and for predicting prognosis and treatment response, individual variation in germline DNA can also play an important role in drug response. Gemcitabine and AraC are two cytidine analogues that are widely used to treat a variety of cancers [@pone.0007765-Heinemann1]--[@pone.0007765-Kindler1]. Only 20% of the pancreatic cancer patients treated with gemcitabine have life expectancy over 1 year. Many side effects such as GI and hematological side effects are associated with the use of these drugs. Therefore, it would be important to identify biomarkers that might help to select responsive patients and avoid side effects during treatment with these drugs.

In a present study, we took advantage of ethnically diverse Coriell "Human Variation Panel" lymphoblastoid cell lines to test the hypothesis that genetic variation across the genome in germline DNA might impact gemcitabine and AraC cytotoxicity. These cell lines were obtained from three different ethnic groups: Caucasian-Americans, African-Americans and Han Chinese-Americans. Although they are Epstein-Barr virus (EBV) transformed cell lines with expression profiles distinctive from those in tumor cells, these cell lines provide an opportunity to query the impact of common genomic variation on drug response [@pone.0007765-Morley1], [@pone.0007765-Tomasson1]--[@pone.0007765-Li1]. Specifically, we have now used these cell lines to perform GWA experiments designed to identify genetic variation that might be associated with variation in gene expression and then, subsequently, with variation in gemcitabine and AraC IC~50~ values. We identified 19 and 30 SNPs associated with gemcitabine and AraC IC~50~ that were also associated with the expression of 29 and 30 genes, respectively. At the same time, this variation in gene expression was associated with IC~50~ values for the two drug. We then focused on 2 SNPs with unknown function in the intron and 5′-flank region (FR) of a gene encoding the IQ motif containing GTPase activating protein 2 (*IQGAP2*),(rs3797418) and a gene encoding transglutaminase 3 (*TGM3*), (rs6082527), respectively. *IQGAP2* (rs3797418) was significantly associated with IC~50~ for both drugs and *TGM3* (rs6082527) was significantly associated with the expression of multiple genes and with gemcitabine IC~50~ values. These two SNPs are not in linkage disequilibrium (LD) with each other. Because gemcitabine is used to treat a variety of solid tumors including pancreatic cancer, in order to validate this association obtained using lymphoblastoid cell lines, we selected two pancreatic tumor cell lines to perform siRNA knock down of three selected genes (*MGMT*, *VAV3* and *GPM6A*) with expression levels that were associated with either or both of the rs3797418 and rs6082527 SNPs. Those results indicated that down-regulation of VAV3 and GPM6A altered gemcitabine or AraC response, as predicted by the association studies. In addition, we also took the advantage of the fact that we had information with regard to SNPs for all of the genes involved in the cytidine analogue activation and deactivation pathway, and performed SNP expression as well as drug cytotoxicity analyses with those genes. These results suggest that a genome-wide approach can help to identify genetic variation that might be important for variation in drug response through the trans-regulation of the expression of multiple genes.

Results {#s2}
=======

Genome-Wide SNP vs. Gemcitabine IC~50~ Association Study {#s2a}
--------------------------------------------------------

A total of 561,464 SNPs were genotyped on the Illumina 550K SNP array and were subjected to quality control prior to performing the association study. As a result, we first removed the 8,222 SNPs that had call rate \<95% as well as the 33,564 SNPs with Minor Allele Frequencies (MAFs) \<5%. Finally, we removed 4,639 SNPs that deviated from Hardy-Weinberg Equilibrium (HWE) using a stringent threshold of p\<0.001. Therefore, a total of 515,039 SNPs were used in a genome-wide SNP analyses for 171 cell lines. [**Figure 1**](#pone-0007765-g001){ref-type="fig"} depicts graphically and **[Table S1](#pone.0007765.s001){ref-type="supplementary-material"} and [S2](#pone.0007765.s002){ref-type="supplementary-material"}** list the 492 SNPs associated with gemcitabine IC~50~ and the 553 SNPs associated with AraC IC~50~ with p-values \<10^−3^. 58 and 68 SNPs among these 492 and 553 SNPs had p-values \<10^−4^, respectively. These 58 and 68 SNPs were in or near 47 or 59 unique genes on the basis of the annotation provided by Illumina, genome build 36.1. 14 of those 58 SNPs were in 3′-flanking regions, 19 in 5′-flanking regions, 23 in intragenic regions of the closest gene, while only two were in the coding regions for the *PIGB* and *HLA-DRA* genes. The top three SNPs from the GWAS, rs4272382 (p = 6.14×10^−7^), rs3775182 (9.67×10^−7^) and rs2290344 (3.65×10^−6^), were in genes encoding claudin 23, MAPK10 and PIGB. For the 68 top SNPs associated with AraC IC~50~ in 59 unique genes, 28 SNPs were in 3′-flanking regions, 17 in 5′-flanking regions and 23 in introns. None were in coding regions. The top three SNPs for AraC were rs2604376 (p = 1.84×10^−6^), rs9512755 (p = 2.54×10^−6^) and rs2595500 (p = 2.63×10^−6^) in the *TUSC3*, *LNX2* and *ZNF215* genes. When we compared gemcitabine and AraC, among the top SNPs that were associated with drug IC~50~ values (p\<0.001), only 49 were common to both drugs (**[Table S3](#pone.0007765.s003){ref-type="supplementary-material"} and** [**Figure 2**](#pone-0007765-g002){ref-type="fig"}).

![Genome-wide SNP association with drug IC~50~.\
(A). Genome-wide SNP-gemcitabine IC~50~ association data. (B). Genome-wide SNP-AraC IC~50~ association data. Genome-wide SNPs were obtained for all 171 cell lines using Illumina 550K Beadchips. Genome-wide SNP association analysis was then performed with gemcitabine IC~50~ as the drug-response phenotype (n = 171). The y-axis is the −log10 (p-value) for the SNP. SNPs are plotted on the x-axis on the basis of their chromosomal locations. The "cut-off" p-value of 0.001 is highlighted with a red line.](pone.0007765.g001){#pone-0007765-g001}

![Top candidate SNPs that overlapped between gemcitabine and AraC.\
49 SNPs were common (p\<0.001) among 442 unique SNPs associated with gemcitabine and 504 associated with AraC.](pone.0007765.g002){#pone-0007765-g002}

SNP and Gene Expression Association {#s2b}
-----------------------------------

Among the above associated 492 associated with gemcitabine IC~50~, we observed that 100 unique SNPs, located within or near 78 genes on the basis of the Illumina annotation were associated with variation in the expression of 296 probesets (220 unique genes) with a cutoff of p-values \<10^−6^. Among the 553 SNPs associated with AraC IC~50~, 140 unique SNPs within or near 123 genes were associated with variation in expression of 843 (563 unique genes) expression probesets (**[Table S4](#pone.0007765.s004){ref-type="supplementary-material"} and [S5](#pone.0007765.s005){ref-type="supplementary-material"}**). Only 12 out of the 100 SNPs or 32 out of the 140 SNPs were in cis-regulatory regions for gemcitabine and AraC, respectively, defined as 5 Mb on either side of the gene, while the rest of the SNPs were localized in trans-regulatory regions, consistent with previous findings [@pone.0007765-Morley1], [@pone.0007765-Huang1]--[@pone.0007765-Bystrykh1].

Gene Expression and IC~50~ Association {#s2c}
--------------------------------------

Among the 296 expression probesets associated with the 100 unique SNPs for gemcitabine, we determined that 35 expression probesets were also associated with gemcitabine IC~50~ values (p\<0.001). These 35 probesets represented 29 genes. By performing the same analysis for AraC, we identified 60 expression probesets that represented 54 genes which were associated with AraC IC~50~ values (p\<0.001). [**Figure 3**](#pone-0007765-g003){ref-type="fig"} showed our integrated analysis strategy, a strategy that included SNP, gemcitabine and gene expression data. This analysis resulted in the identification of 19 SNPs close to or within 16 genes that were associated with gemcitabine IC~50~ values through an influence on the expression of 29 genes represented by 35 expression probesets ([**Table 1**](#pone-0007765-t001){ref-type="table"}). The same type of analysis resulted in the identification of 30 SNPs close to or within 30 genes that were associated with AraC IC~50~ values through an influence on the expression of 54 genes represented by 60 expression probesets ([**Table 2**](#pone-0007765-t002){ref-type="table"}). Among the top candidate SNPs, rs3797418 (A/C), a SNP located in an intron of *IQGAP2*, was significantly associated with the expression of multiple genes and IC~50~ values for both drug. Therefore, this SNP and gene were selected for further functional verification. In addition, a second SNP, rs6082527 (A/G), located in the 5′-FR of *TGM3*, which was only associated with gemcitabine IC~50~ values, was also selected for further functional study because of its significant association with the expression of multiple genes, and these genes were also significantly associated with gemcitabine cytotoxicity, with p values ranging from 10^−4^ to 10^−8^ ([**Tables 1**](#pone-0007765-t001){ref-type="table"} **and** [**2**](#pone-0007765-t002){ref-type="table"}). Although the SNP in *TGM3* was not significantly associated with AraC IC~50~ values, given the similarity between these two drugs, we also performed functional studies for *TGM3* and its downstream gene *GPM6A* with AraC. Specifically, rs3797418 was associated with the expression of 10 individual genes for gemcitabine and 7 for AraC. rs6082527 was associated with 6 probesets that targeted 5 individual genes.

![Strategy applied in these studies.\
A genome-wide SNP association study was performed with a drug-related phenotype, gemcitabine or AraC cytotoxicity (IC~50~). SNPs associated with cytotoxicity (p\<10^−3^) were used to perform an association study with 54,000 expression probesets to identify SNPs that were associated with both gene expression (p\<10^−6^) and with gemcitabine or AraC IC~50~. Finally, an association study was performed with gene expression and gemcitabine or AraC IC~50~ to identify SNPs that might be associated with drug IC~50~ values through an influence on gene expression.](pone.0007765.g003){#pone-0007765-g003}
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###### Top candidate SNPs and probe sets that were associated with gemcitabine IC~50~.

![](pone.0007765.t001){#pone-0007765-t001-1}

  SNPs             Probe sets   SNP vs Expression   Expression vs IC50   SNP vs IC50                                                                                                                          
  --------------- ------------ ------------------- -------------------- ------------- ------------------ -------- ------------------------- ----------- -------------- ----------- -------------- ----------- --------------
  rs1423300            5            ADAMTS12              intron            0.526         209303_at         5              NDUFS4              −0.40       2.00E-07       0.32        2.27E-05       −0.28       3.57E-04
  rs2118524            12             BTG1            flanking_5UTR         0.088         219104_at         11             RNF141              0.39        5.74E-07       −0.33       1.07E-05       −0.26       9.95E-04
  rs2118524            12             BTG1            flanking_5UTR         0.088         231186_at         14     FLJ43390///LOC100128793     0.39        5.95E-07       −0.29       1.09E-04       −0.26       9.95E-04
  rs1809180            15             CHSY1           flanking_3UTR         0.173         201462_at         7               SCRN1              −0.41       8.28E-08       0.34        6.47E-06       −0.27       9.12E-04
  rs453169             16           FLJ32252          flanking_3UTR         0.056         231851_at         1              RAVER2              0.45        3.23E-09       −0.30       6.63E-05       −0.27       7.79E-04
  rs11215406           11             IGSF4               intron            0.14          1556095_at        15             UNC13C              0.39        3.22E-07       −0.32       1.57E-05       −0.27       6.70E-04
  rs11215406           11             IGSF4               intron            0.14        1569969_a\_at       15             UNC13C              0.38        9.91E-07       −0.30       5.46E-05       −0.27       6.70E-04
  **rs3797418**      **5**         **IQGAP2**           **intron**        **0.102**    **203726_s\_at**   **18**          **LAMA3**          **0.41**    **9.07E-08**   **−0.44**   **1.23E-09**   **−0.27**   **8.11E-04**
  **rs3797418**      **5**         **IQGAP2**           **intron**        **0.102**    **204105_s\_at**   **7**           **NRCAM**          **0.43**    **1.65E-08**   **−0.28**   **1.75E-04**   **−0.27**   **8.11E-04**
  **rs3797418**      **5**         **IQGAP2**           **intron**        **0.102**     **204880_at**     **10**          **MGMT**           **−0.41**   **1.22E-07**   **0.40**    **5.49E-08**   **−0.27**   **8.11E-04**
  **rs3797418**      **5**         **IQGAP2**           **intron**        **0.102**    **205925_s\_at**   **1**           **RAB3B**          **0.39**    **3.94E-07**   **−0.29**   **1.35E-04**   **−0.27**   **8.11E-04**
  **rs3797418**      **5**         **IQGAP2**           **intron**        **0.102**    **205931_s\_at**   **7**           **CREB5**          **0.38**    **9.37E-07**   **−0.26**   **5.71E-04**   **−0.27**   **8.11E-04**
  **rs3797418**      **5**         **IQGAP2**           **intron**        **0.102**     **210058_at**     **6**          **MAPK13**          **0.39**    **3.20E-07**   **−0.27**   **3.09E-04**   **−0.27**   **8.11E-04**
  **rs3797418**      **5**         **IQGAP2**           **intron**        **0.102**    **210059_s\_at**   **6**          **MAPK13**          **0.46**    **1.29E-09**   **−0.31**   **4.70E-05**   **−0.27**   **8.11E-04**
  **rs3797418**      **5**         **IQGAP2**           **intron**        **0.102**     **213056_at**     **3**          **FRMD4B**          **0.39**    **5.54E-07**   **−0.30**   **6.37E-05**   **−0.27**   **8.11E-04**
  **rs3797418**      **5**         **IQGAP2**           **intron**        **0.102**    **216959_x\_at**   **7**           **NRCAM**          **0.43**    **1.54E-08**   **−0.29**   **9.36E-05**   **−0.27**   **8.11E-04**
  **rs3797418**      **5**         **IQGAP2**           **intron**        **0.102**    **218651_s\_at**   **15**          **LARP6**          **0.40**    **2.39E-07**   **−0.31**   **3.71E-05**   **−0.27**   **8.11E-04**
  **rs3797418**      **5**         **IQGAP2**           **intron**        **0.102**    **218806_s\_at**   **1**           **VAV3**           **0.41**    **8.14E-08**   **−0.37**   **5.79E-07**   **−0.27**   **8.11E-04**
  **rs3797418**      **5**         **IQGAP2**           **intron**        **0.102**     **218807_at**     **1**           **VAV3**           **0.49**    **9.16E-11**   **−0.39**   **1.49E-07**   **−0.27**   **8.11E-04**
  **rs3797418**      **5**         **IQGAP2**           **intron**        **0.102**     **227123_at**     **1**           **RAB3B**          **0.47**    **4.56E-10**   **−0.26**   **4.85E-04**   **−0.27**   **8.11E-04**
  **rs3797418**      **5**         **IQGAP2**           **intron**        **0.102**     **232280_at**     **14**        **SLC25A29**         **0.39**    **3.24E-07**   **−0.35**   **2.99E-06**   **−0.27**   **8.11E-04**
  rs2290344            15             PIGB                coding            0.254        242760_x\_at       15              PIGB               −0.41       1.43E-07       −0.29       8.98E-05       0.36        3.65E-06
  rs8024695            15             PIGB                intron            0.287        242760_x\_at       15              PIGB               −0.38       7.05E-07       −0.29       8.98E-05       0.34        1.43E-05
  rs12188464           5             PIK3R1           flanking_3UTR         0.459        201334_s\_at       11            ARHGEF12             0.38        9.03E-07       −0.34       5.35E-06       −0.32       4.57E-05
  rs7713001            5             PIK3R1           flanking_3UTR         0.459        201334_s\_at       11            ARHGEF12             0.38        9.03E-07       −0.34       5.35E-06       −0.32       4.57E-05
  rs6625401            23             PJA1            flanking_3UTR         0.351        214908_s\_at       7               TRRAP              0.39        4.31E-07       −0.27       3.28E-04       −0.31       8.03E-05
  rs2217881            1              PLD5                intron            0.08          231186_at         14     FLJ43390///LOC100128793     0.44        1.46E-08       −0.29       1.09E-04       −0.29       3.35E-04
  rs7313937            12             PTPRR               intron            0.088        211572_s\_at       20             SLC23A2             0.41        8.23E-08       −0.33       7.50E-06       −0.27       7.17E-04
  rs4896870            6              RAB32           flanking_5UTR         0.117        223194_s\_at       6             SLC22A23             0.45        2.92E-09       −0.29       1.24E-04       −0.27       6.66E-04
  rs4896870            6              RAB32           flanking_5UTR         0.117         242629_at         1               \-\--              0.40        2.83E-07       −0.28       2.21E-04       −0.27       6.66E-04
  rs4896870            6              RAB32           flanking_5UTR         0.117          47560_at         19              LPHN1              0.38        9.73E-07       −0.28       1.73E-04       −0.27       6.66E-04
  rs907609             11             SYT8                coding            0.082        205925_s\_at       1               RAB3B              0.38        6.49E-07       −0.29       1.35E-04       −0.28       4.12E-04
  **rs6082527**      **20**         **TGM3**        **flanking_5UTR**     **0.058**     **204880_at**     **10**          **MGMT**           **−0.41**   **8.06E-08**   **0.40**    **5.49E-08**   **−0.28**   **4.86E-04**
  **rs6082527**      **20**         **TGM3**        **flanking_5UTR**     **0.058**     **209469_at**     **4**           **GPM6A**          **0.42**    **4.67E-08**   **−0.35**   **2.08E-06**   **−0.28**   **4.86E-04**
  **rs6082527**      **20**         **TGM3**        **flanking_5UTR**     **0.058**    **209470_s\_at**   **4**           **GPM6A**          **0.40**    **1.99E-07**   **−0.34**   **6.37E-06**   **−0.28**   **4.86E-04**
  **rs6082527**      **20**         **TGM3**        **flanking_5UTR**     **0.058**     **224325_at**     **10**          **FZD8**           **0.41**    **1.01E-07**   **−0.30**   **5.69E-05**   **−0.28**   **4.86E-04**
  **rs6082527**      **20**         **TGM3**        **flanking_5UTR**     **0.058**    **224499_s\_at**   **12**          **AICDA**          **−0.40**   **2.07E-07**   **0.31**    **3.71E-05**   **−0.28**   **4.86E-04**
  **rs6082527**      **20**         **TGM3**        **flanking_5UTR**     **0.058**    **225784_s\_at**   **23**        **KIAA1166**         **−0.43**   **2.33E-08**   **0.28**    **2.41E-04**   **−0.28**   **4.86E-04**
  rs1153942            1             TP53BP2              intron            0.118         218801_at         13             UGCGL2              −0.45       3.26E-09       −0.25       8.80E-04       0.27        9.38E-04
  rs612578             19            ZNF626               intron            0.24         202092_s\_at       16             ARL2BP              0.39        3.50E-07       −0.38       2.62E-07       −0.29       3.33E-04
  rs11666947           19            ZNF626           flanking_3UTR         0.06          231186_at         14     FLJ43390///LOC100128793     0.41        1.91E-07       −0.29       1.09E-04       −0.28       6.40E-04

35 probe sets (29 unique genes) associated with 19 SNPs (16 unique SNP-nearby genes) were significantly correlated with gemcitabine IC~50~. Genes that were associated with the two SNPs in *IQGAP2* and *TGM3* are bolded. p-value for each association are indicated. R values represent the correlation coefficient for each association.

10.1371/journal.pone.0007765.t002

###### Top candidate SNPs and probe sets that were associated with AraC IC~50~.

![](pone.0007765.t002){#pone-0007765-t002-2}

  SNPs             Probesets   SNP vs Expression(54K)   Expression (54K) vs GI~50~   SNP vs GI~50~                                                                                                                  
  --------------- ----------- ------------------------ ---------------------------- --------------- ------------------ -------- -------------- ------------ -------------- ------------ -------------- ------------ --------------
  rs11215406          11               IGSF4                      intron                 0.139          1556095_at        15        UNC13C        0.394        3.22E-07       −0.351       7.64E-06       −0.354       1.60E-06
  rs11215406          11               IGSF4                      intron                 0.139        1569969_a\_at       15        UNC13C        0.379        9.91E-07       −0.351       7.64E-06       −0.332       7.56E-06
  rs10208516           2               CTNNA2                 flanking_3UTR              0.052          214018_at         12        GRIP1         0.410        9.73E-08       0.342        1.37E-05       0.270        3.23E-04
  rs10208516           2               CTNNA2                 flanking_3UTR              0.052          1565812_at        5         TRIM36        0.414        7.34E-08       0.342        1.37E-05       0.268        3.53E-04
  rs10208516           2               CTNNA2                 flanking_3UTR              0.052          205088_at         23        MAMLD1        0.409        1.02E-07       0.342        1.37E-05       0.263        4.64E-04
  rs10208516           2               CTNNA2                 flanking_3UTR              0.052          203443_at         11         EML3         0.422        3.57E-08       0.342        1.37E-05       0.255        6.84E-04
  rs10208516           2               CTNNA2                 flanking_3UTR              0.052          206696_at         23        GPR143        0.413        7.89E-08       0.342        1.37E-05       0.248        9.80E-04
  rs888468            12                FGF6                  flanking_3UTR              0.182         211572_s\_at       20       SLC23A2        0.405        1.43E-07       −0.341       1.45E-05       −0.264       4.25E-04
  rs11136070           8               DUSP4                  flanking_5UTR              0.052         209756_s\_at       2          MYCN         0.421        4.04E-08       0.328        3.15E-05       0.312        2.73E-05
  rs11136070           8               DUSP4                  flanking_5UTR              0.052          1553755_at        19        NXNL1         0.395        3.14E-07       0.328        3.15E-05       0.312        2.82E-05
  rs11136070           8               DUSP4                  flanking_5UTR              0.052          1554782_at        2        C2orf19        0.453        2.64E-09       0.328        3.15E-05       0.304        4.58E-05
  rs11136070           8               DUSP4                  flanking_5UTR              0.052         242071_x\_at       10        ITGA8         0.411        8.62E-08       0.328        3.15E-05       0.276        2.22E-04
  rs11136070           8               DUSP4                  flanking_5UTR              0.052          213417_at         17         TBX2         0.475        3.21E-10       0.328        3.15E-05       0.274        2.51E-04
  rs11136070           8               DUSP4                  flanking_5UTR              0.052          240729_at         3        C3orf44        0.382        7.93E-07       0.328        3.15E-05       0.271        3.04E-04
  rs11136070           8               DUSP4                  flanking_5UTR              0.052          214018_at         12        GRIP1         0.490        7.06E-11       0.328        3.15E-05       0.270        3.23E-04
  rs11136070           8               DUSP4                  flanking_5UTR              0.052          1565812_at        5         TRIM36        0.461        1.25E-09       0.328        3.15E-05       0.268        3.53E-04
  rs11136070           8               DUSP4                  flanking_5UTR              0.052        1569002_x\_at       8          BMP1         0.404        1.50E-07       0.328        3.15E-05       0.266        3.80E-04
  rs11136070           8               DUSP4                  flanking_5UTR              0.052         205947_s\_at       7         VIPR2         0.446        4.84E-09       0.328        3.15E-05       0.265        4.20E-04
  rs11136070           8               DUSP4                  flanking_5UTR              0.052          205088_at         23        MAMLD1        0.499        2.89E-11       0.328        3.15E-05       0.263        4.64E-04
  rs11136070           8               DUSP4                  flanking_5UTR              0.052          235820_at         12     LOC100130219     0.430        1.89E-08       0.328        3.15E-05       0.262        4.90E-04
  rs11136070           8               DUSP4                  flanking_5UTR              0.052          215527_at         6        KHDRBS2        0.428        2.17E-08       0.328        3.15E-05       0.259        5.71E-04
  rs11136070           8               DUSP4                  flanking_5UTR              0.052          244036_at         NA        \-\--         0.480        2.01E-10       0.328        3.15E-05       0.257        6.26E-04
  rs11136070           8               DUSP4                  flanking_5UTR              0.052          203443_at         11         EML3         0.438        9.32E-09       0.328        3.15E-05       0.255        6.84E-04
  rs11136070           8               DUSP4                  flanking_5UTR              0.052          230249_at         8        KHDRBS3        0.423        3.49E-08       0.328        3.15E-05       0.255        6.96E-04
  rs11136070           8               DUSP4                  flanking_5UTR              0.052          215953_at         1      DKFZP564C196     0.387        5.72E-07       0.328        3.15E-05       0.252        8.12E-04
  rs11136070           8               DUSP4                  flanking_5UTR              0.052          206696_at         23        GPR143        0.455        2.19E-09       0.328        3.15E-05       0.248        9.80E-04
  rs970084            20                SNPH                  flanking_5UTR              0.081         222895_s\_at       14        BCL11B        0.416        5.93E-08       −0.327       3.21E-05       −0.271       3.03E-04
  rs970084            20                SNPH                  flanking_5UTR              0.081         219528_s\_at       14        BCL11B        0.390        4.46E-07       −0.327       3.21E-05       −0.269       3.36E-04
  rs12412561          10               PCDH15                 flanking_3UTR              0.069          205924_at         1         RAB3B         0.416        6.00E-08       −0.321       4.68E-05       −0.265       4.15E-04
  rs12128558           1               NPHP4                  flanking_3UTR              0.055          1569419_at        NA        \-\--         0.441        7.30E-09       0.317        5.99E-05       0.333        6.90E-06
  rs12128558           1               NPHP4                  flanking_3UTR              0.055          234896_at         NA        \-\--         0.465        8.89E-10       0.317        5.99E-05       0.259        5.49E-04
  rs11876487          18               GATA6                  flanking_3UTR              0.069         205947_s\_at       7         VIPR2         0.406        1.28E-07       0.313        7.16E-05       0.265        4.20E-04
  rs11876487          18               GATA6                  flanking_3UTR              0.069          215953_at         1      DKFZP564C196     0.403        1.68E-07       0.313        7.16E-05       0.252        8.12E-04
  rs613359             4             LOC132321                flanking_3UTR              0.061          1554782_at        2        C2orf19        0.402        1.78E-07       0.313        7.52E-05       0.304        4.58E-05
  rs613359             4             LOC132321                flanking_3UTR              0.061         206401_s\_at       17         MAPT         0.387        5.62E-07       0.313        7.52E-05       0.297        6.81E-05
  rs613359             4             LOC132321                flanking_3UTR              0.061          230666_at         7       tcag7.1238      0.401        1.95E-07       0.313        7.52E-05       0.288        1.19E-04
  rs613359             4             LOC132321                flanking_3UTR              0.061         242071_x\_at       10        ITGA8         0.385        6.44E-07       0.313        7.52E-05       0.276        2.22E-04
  rs613359             4             LOC132321                flanking_3UTR              0.061          213417_at         17         TBX2         0.436        1.17E-08       0.313        7.52E-05       0.274        2.51E-04
  rs613359             4             LOC132321                flanking_3UTR              0.061          214018_at         12        GRIP1         0.451        3.20E-09       0.313        7.52E-05       0.270        3.23E-04
  rs613359             4             LOC132321                flanking_3UTR              0.061          1565812_at        5         TRIM36        0.421        4.11E-08       0.313        7.52E-05       0.268        3.53E-04
  rs613359             4             LOC132321                flanking_3UTR              0.061        1569002_x\_at       8          BMP1         0.407        1.27E-07       0.313        7.52E-05       0.266        3.80E-04
  rs613359             4             LOC132321                flanking_3UTR              0.061         205947_s\_at       7         VIPR2         0.461        1.20E-09       0.313        7.52E-05       0.265        4.20E-04
  rs613359             4             LOC132321                flanking_3UTR              0.061          205088_at         23        MAMLD1        0.438        1.00E-08       0.313        7.52E-05       0.263        4.64E-04
  rs613359             4             LOC132321                flanking_3UTR              0.061          235820_at         12     LOC100130219     0.398        2.52E-07       0.313        7.52E-05       0.262        4.90E-04
  rs613359             4             LOC132321                flanking_3UTR              0.061          215527_at         6        KHDRBS2        0.403        1.62E-07       0.313        7.52E-05       0.259        5.71E-04
  rs613359             4             LOC132321                flanking_3UTR              0.061          215953_at         1      DKFZP564C196     0.426        2.72E-08       0.313        7.52E-05       0.252        8.12E-04
  rs613359             4             LOC132321                flanking_3UTR              0.061          224168_at         NA        TXNDC2        0.383        7.59E-07       0.313        7.52E-05       0.251        8.19E-04
  rs613359             4             LOC132321                flanking_3UTR              0.061          206696_at         23        GPR143        0.379        9.67E-07       0.313        7.52E-05       0.248        9.80E-04
  rs10780183           9               EHMT1                  flanking_5UTR              0.127          225532_at         18       CABLES1        −0.386       5.90E-07       −0.302       1.36E-04       0.271        2.92E-04
  rs7612441            3               LRIG1                  flanking_5UTR              0.145         236565_s\_at       15        LARP6         0.445        5.28E-09       −0.298       1.69E-04       −0.274       2.49E-04
  **rs3797418**      **5**           **IQGAP2**                 **intron**             **0.101**      **204880_at**     **10**     **MGMT**     **−0.407**   **1.22E-07**   **−0.296**   **1.85E-04**   **0.332**    **7.44E-06**
  **rs3797418**      **5**           **IQGAP2**                 **intron**             **0.101**     **204105_s\_at**   **7**     **NRCAM**     **0.432**    **1.65E-08**   **−0.296**   **1.85E-04**   **−0.297**   **6.80E-05**
  **rs3797418**      **5**           **IQGAP2**                 **intron**             **0.101**     **218651_s\_at**   **15**    **LARP6**     **0.398**    **2.39E-07**   **−0.296**   **1.85E-04**   **−0.289**   **1.11E-04**
  **rs3797418**      **5**           **IQGAP2**                 **intron**             **0.101**      **210058_at**     **6**     **MAPK13**    **0.394**    **3.20E-07**   **−0.296**   **1.85E-04**   **−0.284**   **1.48E-04**
  **rs3797418**      **5**           **IQGAP2**                 **intron**             **0.101**      **218807_at**     **1**      **VAV3**     **0.488**    **9.16E-11**   **−0.296**   **1.85E-04**   **−0.279**   **1.95E-04**
  **rs3797418**      **5**           **IQGAP2**                 **intron**             **0.101**     **203726_s\_at**   **18**    **LAMA3**     **0.411**    **9.07E-08**   **−0.296**   **1.85E-04**   **−0.277**   **2.15E-04**
  **rs3797418**      **5**           **IQGAP2**                 **intron**             **0.101**     **216959_x\_at**   **7**     **NRCAM**     **0.433**    **1.54E-08**   **−0.296**   **1.85E-04**   **−0.274**   **2.52E-04**
  **rs3797418**      **5**           **IQGAP2**                 **intron**             **0.101**     **210059_s\_at**   **6**     **MAPK13**    **0.461**    **1.29E-09**   **−0.296**   **1.85E-04**   **−0.260**   **5.40E-04**
  **rs3797418**      **5**           **IQGAP2**                 **intron**             **0.101**      **213056_at**     **3**     **FRMD4B**    **0.387**    **5.54E-07**   **−0.296**   **1.85E-04**   **−0.259**   **5.45E-04**
  **rs3797418**      **5**           **IQGAP2**                 **intron**             **0.101**     **218806_s\_at**   **1**      **VAV3**     **0.412**    **8.14E-08**   **−0.296**   **1.85E-04**   **−0.248**   **9.46E-04**
  rs17637119           3               CADPS                      intron                 0.069          204880_at         10         MGMT         −0.382       8.06E-07       −0.296       1.88E-04       0.332        7.44E-06
  rs17637119           3               CADPS                      intron                 0.069          204866_at         23        PHF16         0.392        3.94E-07       −0.296       1.88E-04       −0.311       3.00E-05
  rs17637119           3               CADPS                      intron                 0.069         204105_s\_at       7         NRCAM         0.421        4.15E-08       −0.296       1.88E-04       −0.297       6.80E-05
  rs17637119           3               CADPS                      intron                 0.069          218807_at         1          VAV3         0.451        3.04E-09       −0.296       1.88E-04       −0.279       1.95E-04
  rs17637119           3               CADPS                      intron                 0.069         203726_s\_at       18        LAMA3         0.404        1.54E-07       −0.296       1.88E-04       −0.277       2.15E-04
  rs17637119           3               CADPS                      intron                 0.069         216959_x\_at       7         NRCAM         0.416        5.89E-08       −0.296       1.88E-04       −0.274       2.52E-04
  rs17637119           3               CADPS                      intron                 0.069         222548_s\_at       2         MAP4K4        0.382        7.91E-07       −0.296       1.88E-04       −0.273       2.63E-04
  rs17637119           3               CADPS                      intron                 0.069         218181_s\_at       2         MAP4K4        0.381        8.73E-07       −0.296       1.88E-04       −0.271       2.94E-04
  rs17637119           3               CADPS                      intron                 0.069         203922_s\_at       23         CYBB         −0.393       3.45E-07       −0.296       1.88E-04       0.265        4.12E-04
  rs17637119           3               CADPS                      intron                 0.069         210059_s\_at       6         MAPK13        0.382        7.87E-07       −0.296       1.88E-04       −0.260       5.40E-04
  rs17637119           3               CADPS                      intron                 0.069          213056_at         3         FRMD4B        0.379        9.66E-07       −0.296       1.88E-04       −0.259       5.45E-04
  rs17637119           3               CADPS                      intron                 0.069          239202_at         NA        \-\--         0.414        7.17E-08       −0.296       1.88E-04       −0.250       8.71E-04
  rs17637119           3               CADPS                      intron                 0.069         218806_s\_at       1          VAV3         0.431        1.81E-08       −0.296       1.88E-04       −0.248       9.46E-04
  rs11796743          23               GSPT2                  flanking_5UTR              0.061          1553755_at        19        NXNL1         0.420        4.75E-08       0.288        2.90E-04       0.312        2.82E-05
  rs1408077            1                CR1                       intron                 0.195          1567320_at        NA       LOC57802       0.403        1.76E-07       0.283        3.85E-04       0.249        9.14E-04
  rs5962901           23                MID2                      intron                 0.067          226529_at         7        TMEM106B       −0.380       9.95E-07       0.280        4.38E-04       −0.276       2.23E-04
  rs5962901           23                MID2                      intron                 0.067          213417_at         17         TBX2         0.408        1.26E-07       0.280        4.38E-04       0.274        2.51E-04
  rs5962901           23                MID2                      intron                 0.067          214018_at         12        GRIP1         0.403        1.78E-07       0.280        4.38E-04       0.270        3.23E-04
  rs5962901           23                MID2                      intron                 0.067          1565812_at        5         TRIM36        0.413        8.17E-08       0.280        4.38E-04       0.268        3.53E-04
  rs5962901           23                MID2                      intron                 0.067          205088_at         23        MAMLD1        0.389        5.18E-07       0.280        4.38E-04       0.263        4.64E-04
  rs5962901           23                MID2                      intron                 0.067          215527_at         6        KHDRBS2        0.385        6.82E-07       0.280        4.38E-04       0.259        5.71E-04
  rs5962901           23                MID2                      intron                 0.067          206696_at         23        GPR143        0.432        1.73E-08       0.280        4.38E-04       0.248        9.80E-04
  rs17183491          15               WDR72                  flanking_5UTR              0.263         227067_x\_at       1        NOTCH2NL       −0.382       9.55E-07       0.280        4.59E-04       −0.256       6.48E-04
  rs6491526           13               CLYBL                      intron                 0.075          214018_at         12        GRIP1         0.398        2.46E-07       0.277        4.84E-04       0.270        3.23E-04
  rs6491526           13               CLYBL                      intron                 0.075        1569002_x\_at       8          BMP1         0.382        7.76E-07       0.277        4.84E-04       0.266        3.80E-04
  rs6491526           13               CLYBL                      intron                 0.075         210961_s\_at       20        ADRA1D        0.380        9.07E-07       0.277        4.84E-04       0.254        7.25E-04
  rs1669748            5              ADAMTS16                flanking_5UTR              0.462          239202_at         NA        \-\--         0.394        3.21E-07       −0.277       4.93E-04       −0.250       8.71E-04
  rs11706227           3               WNT5A                  flanking_3UTR              0.061        1560397_s\_at       NA        KLHL6         −0.384       6.71E-07       0.274        5.61E-04       −0.286       1.33E-04
  rs9833533            3                FHIT                      intron                 0.058          1554782_at        2        C2orf19        0.488        9.19E-11       0.272        6.23E-04       0.304        4.58E-05
  rs9833533            3                FHIT                      intron                 0.058          1570330_at        NA        \-\--         0.386        5.97E-07       0.272        6.23E-04       0.284        1.42E-04
  rs9833533            3                FHIT                      intron                 0.058          214018_at         12        GRIP1         0.424        3.25E-08       0.272        6.23E-04       0.270        3.23E-04
  rs9833533            3                FHIT                      intron                 0.058          1565812_at        5         TRIM36        0.423        3.44E-08       0.272        6.23E-04       0.268        3.53E-04
  rs9833533            3                FHIT                      intron                 0.058         205947_s\_at       7         VIPR2         0.384        6.71E-07       0.272        6.23E-04       0.265        4.20E-04
  rs9833533            3                FHIT                      intron                 0.058          205088_at         23        MAMLD1        0.379        9.83E-07       0.272        6.23E-04       0.263        4.64E-04
  rs9833533            3                FHIT                      intron                 0.058          235820_at         12     LOC100130219     0.446        4.75E-09       0.272        6.23E-04       0.262        4.90E-04
  rs9833533            3                FHIT                      intron                 0.058          215527_at         6        KHDRBS2        0.463        9.78E-10       0.272        6.23E-04       0.259        5.71E-04
  rs9833533            3                FHIT                      intron                 0.058          203443_at         11         EML3         0.401        1.89E-07       0.272        6.23E-04       0.255        6.84E-04
  rs9833533            3                FHIT                      intron                 0.058          230249_at         8        KHDRBS3        0.381        8.25E-07       0.272        6.23E-04       0.255        6.96E-04
  rs9833533            3                FHIT                      intron                 0.058          215953_at         1      DKFZP564C196     0.401        1.99E-07       0.272        6.23E-04       0.252        8.12E-04
  rs9833533            3                FHIT                      intron                 0.058          206696_at         23        GPR143        0.446        4.87E-09       0.272        6.23E-04       0.248        9.80E-04
  rs13197839           6               EGFL11                 flanking_3UTR              0.119          200972_at         15        TSPAN3        −0.382       8.52E-07       0.269        7.47E-04       −0.266       3.94E-04
  rs5984367           23              TGIF2LX                 flanking_5UTR              0.098         207278_s\_at       19        CD209         0.424        3.09E-08       0.268        7.48E-04       0.289        1.10E-04
  rs11770570           7               LHFPL3                     intron                 0.055         209756_s\_at       2          MYCN         0.441        7.77E-09       0.267        7.95E-04       0.312        2.73E-05
  rs11770570           7               LHFPL3                     intron                 0.055          230666_at         7       tcag7.1238      0.400        2.12E-07       0.267        7.95E-04       0.288        1.19E-04
  rs11770570           7               LHFPL3                     intron                 0.055          214454_at         5        ADAMTS2        0.395        3.13E-07       0.267        7.95E-04       0.274        2.55E-04
  rs11770570           7               LHFPL3                     intron                 0.055          214018_at         12        GRIP1         0.426        2.70E-08       0.267        7.95E-04       0.270        3.23E-04
  rs11770570           7               LHFPL3                     intron                 0.055          1565812_at        5         TRIM36        0.456        1.98E-09       0.267        7.95E-04       0.268        3.53E-04
  rs11770570           7               LHFPL3                     intron                 0.055          205088_at         23        MAMLD1        0.446        4.60E-09       0.267        7.95E-04       0.263        4.64E-04
  rs11770570           7               LHFPL3                     intron                 0.055          235820_at         12     LOC100130219     0.442        6.92E-09       0.267        7.95E-04       0.262        4.90E-04
  rs11770570           7               LHFPL3                     intron                 0.055          203443_at         11         EML3         0.424        3.05E-08       0.267        7.95E-04       0.255        6.84E-04
  rs11770570           7               LHFPL3                     intron                 0.055          244522_at         11        SYVN1         0.407        1.19E-07       0.267        7.95E-04       0.248        9.64E-04
  rs11770570           7               LHFPL3                     intron                 0.055          206696_at         23        GPR143        0.422        3.65E-08       0.267        7.95E-04       0.248        9.80E-04
  rs11063679          12                NTF3                  flanking_5UTR              0.075          205088_at         23        MAMLD1        0.461        1.19E-09       0.265        8.56E-04       0.263        4.64E-04
  rs5768857           22               CELSR1                     intron                 0.127         209310_s\_at       11        CASP4         0.381        8.40E-07       0.265        8.57E-04       0.267        3.65E-04
  rs4730550            7               IFRD1                      intron                 0.064         218229_s\_at       1          POGK         −0.401       2.18E-07       0.266        8.73E-04       −0.256       6.58E-04
  rs8180101            3                GBE1                  flanking_5UTR              0.081         205982_x\_at       8         SFTPC         0.393        3.64E-07       0.264        8.91E-04       0.248        9.83E-04
  rs772492             4             LOC285513                flanking_5UTR              0.173          213056_at         3         FRMD4B        0.379        9.81E-07       −0.264       8.98E-04       −0.259       5.45E-04
  rs549467             4              RAP1GDS1                flanking_5UTR              0.069         216030_s\_at       20        SEMG2         0.436        1.15E-08       0.263        9.43E-04       0.332        7.74E-06

60 probe sets (54 unique genes) associated with 30 SNPs (30 unique SNP-nearby genes) were significantly correlated with AraC IC50. Genes that were associated with SNPs in IQGAP2 are bolded for AraC, too. p-value for each association are indicated. R values represent the correlation coefficient for each association.

Cytidine Analogue Pathway Gene Analysis {#s2d}
---------------------------------------

Gemcitabine and AraC share the same metabolism pathway that activates these drugs in cells. There is a total of 19 genes within this pathway (**[Table S6](#pone.0007765.s006){ref-type="supplementary-material"}**). Many previous pharmacogenetic studies have been focused on genetic variation in genes within this pathway, and there is evidence showing that variation in the expression of genes within this pathway can influence response to cytidine analogues [@pone.0007765-Smid1], [@pone.0007765-Schoch1], [@pone.0007765-Seve1]. Therefore, we took the advantage of the genome-wide SNP data and selected all SNPs within pathway genes that were present on the Illumina 550K chip to perform an analysis among SNP, expression and gemcitabine and AraC IC~50~ values for these pathway genes. A total of 749 SNPs for cytidine analogue pathway genes were present on the Illumina 550K chip. Association of gemcitabine IC~50~ with SNPs in pathway genes identified 38 SNPs within or close to 8 genes with p-values \<0.05, while 23 SNPs close to 9 genes were significantly associated with AraC IC~50~ values with p-values \<0.05 ([**Tables 3**](#pone-0007765-t003){ref-type="table"} and [**4**](#pone-0007765-t004){ref-type="table"}). To determine the association of SNPs with cis-regulation of pathway gene expression, we associated all of these SNPs with expression for all genes within the pathway. That analysis identified 24 cis-acting SNPs that regulate the expression of pathway genes with p-values \<0.0001 ([**Table 5**](#pone-0007765-t005){ref-type="table"}). The top three SNPs (p = 7.54×10^−33^, 1.54×10^−32^ and 2.69×10^−10^, respectively) were all mapped to the *NT5C3L1* gene, a nucleotidase family member ([**Table 5**](#pone-0007765-t005){ref-type="table"}).

10.1371/journal.pone.0007765.t003

###### Top 38 significant SNPs within or close to 8 pathway genes associated with gemcitabine IC~50~ values (p\<0.05).

![](pone.0007765.t003){#pone-0007765-t003-3}

  SNP           r-value   p-value   q-value    N     MAF    Chr   Position   Genome Build   Gene Symbol        Gene          Location      Location Relative to Gene
  ------------ --------- --------- --------- ----- ------- ----- ---------- -------------- ------------- ---------------- --------------- ---------------------------
  rs2037067      0.269     0.001    0.82119   170   0.471    4    1.84E+08       36.1          DCTD       NM_001012732.1   flanking_3UTR            −237660
  rs3775289      0.227     0.005    0.82119   170   0.203    4    72081538       36.1           DCK        NM_000788.1        Intron                 −1110
  rs4308342      0.227     0.005    0.82119   170   0.203    4    72103069       36.1           DCK        NM_000788.1        Intron                 −3879
  rs956727      −0.218     0.007    0.82119   171   0.117    9    86036753       36.1         SLC28A3      NM_022127.1     flanking_3UTR            −46159
  rs515583       0.211     0.009    0.82119   171   0.19     6    85933010       36.1          NT5E        NM_002526.1     flanking_5UTR            −283518
  rs13144500    −0.205     0.011    0.82119   171   0.123    4    1.84E+08       36.1          DCTD       NM_001012732.1   flanking_3UTR            −335310
  rs12500335    −0.202     0.013    0.82119   170   0.091    4    1.84E+08       36.1          DCTD       NM_001012732.1   flanking_3UTR            −103463
  rs3966882      0.202     0.013    0.82119   168   0.318    6    85938190       36.1          NT5E        NM_002526.1     flanking_5UTR            −278338
  rs10006225     0.200     0.013    0.82119   171   0.064    4    1.84E+08       36.1          DCTD       NM_001012732.1   flanking_3UTR            −102248
  rs1932660      0.200     0.013    0.82119   171   0.234    9    86017079       36.1         SLC28A3      NM_022127.1     flanking_3UTR            −65833
  rs4877822      0.200     0.013    0.82119   171   0.234    9    86021002       36.1         SLC28A3      NM_022127.1     flanking_3UTR            −61910
  rs7874528     −0.198     0.014    0.82119   171   0.17     9    86020319       36.1         SLC28A3      NM_022127.1     flanking_3UTR            −62593
  rs9472236      0.196     0.015    0.82119   171   0.225    6    44314728       36.1         SLC29A1      NM_004955.1     flanking_3UTR             −4872
  rs1570933      0.196     0.015    0.82119   171   0.292    6    85937335       36.1          NT5E        NM_002526.1     flanking_5UTR            −279193
  rs17087049    −0.194     0.017    0.82119   171   0.208    9    86104192       36.1         SLC28A3      NM_022127.1        Intron                 −124
  rs10780659    −0.193     0.017    0.82119   171   0.146    9    86071310       36.1         SLC28A3      NM_022127.1     flanking_3UTR            −11602
  rs7173860      0.192     0.017    0.82119   171   0.465   15    83230545       36.1         SLC28A1      NM_004213.3        Intron                 −362
  rs7597224      0.189     0.019    0.85358   171   0.342    2    18829103       36.1         NT5C1B      NM_001002006.1   flanking_5UTR            −194784
  rs12683783    −0.188     0.020    0.82119   171   0.126    9    86060628       36.1         SLC28A3      NM_022127.1     flanking_3UTR            −22284
  rs10122651    −0.188     0.020    0.82119   171   0.468    9    86123704       36.1         SLC28A3      NM_022127.1        Intron                 −5515
  rs9294329     −0.187     0.021    0.82119   171   0.295    6    85958337       36.1          NT5E        NM_002526.1     flanking_5UTR            −258191
  rs10780663    −0.186     0.022    0.82119   170   0.465    9    86120882       36.1         SLC28A3      NM_022127.1        Intron                 −2693
  rs9362176     −0.181     0.025    0.82119   171   0.152    6    86036174       36.1          NT5E        NM_002526.1     flanking_5UTR            −180354
  rs4585823     −0.179     0.026    0.82119   171   0.132    9    86094005       36.1         SLC28A3      NM_022127.1        Intron                 −884
  rs12684950    −0.178     0.027    0.82119   171   0.155    9    86066751       36.1         SLC28A3      NM_022127.1     flanking_3UTR            −16161
  rs556388       0.178     0.028    0.82119   171   0.447    8    1.03E+08       36.1          RRM2B       NM_015713.3     flanking_3UTR            −110177
  rs10955282     0.179     0.028    0.82119   170   0.488    8    1.03E+08       36.1          RRM2B       NM_015713.3     flanking_3UTR            −39785
  rs10780656     0.178     0.028    0.82998   171   0.196    9    86031222       36.1         SLC28A3      NM_022127.1     flanking_3UTR            −51690
  rs1321742     −0.175     0.032    0.82119   170   0.444    6    85937908       36.1          NT5E        NM_002526.1     flanking_5UTR            −278620
  rs501344       0.172     0.034    0.83550   171   0.327    8    1.03E+08       36.1          RRM2B       NM_015713.3     flanking_3UTR            −102158
  rs3743162      0.171     0.035    0.82119   171   0.129   15    83231973       36.1         SLC28A1      NM_201651.1        Intron                  −7
  rs11885014    −0.173     0.035    0.82119   167   0.272    2    18810796       36.1         NT5C1B      NM_001002006.1   flanking_5UTR            −176477
  rs9990999      0.170     0.037    0.83550   169   0.352    4    1.84E+08       36.1          DCTD        NM_001921.2        Intron                 −8215
  rs944664      −0.166     0.041    0.82119   171   0.444    6    85945694       36.1          NT5E        NM_002526.1     flanking_5UTR            −270834
  rs4877824      0.165     0.042    0.82119   171   0.38     9    86045679       36.1         SLC28A3      NM_022127.1     flanking_3UTR            −37233
  rs2251530     −0.163     0.044    0.82119   171   0.386    9    86002760       36.1         SLC28A3      NM_022127.1     flanking_3UTR            −80152
  rs4507403      0.164     0.046    0.82119   166   0.41     4    1.84E+08       36.1          DCTD       NM_001012732.1   flanking_3UTR            −251819
  rs6850978      0.159     0.050    0.82119   171   0.424    4    1.84E+08       36.1          DCTD       NM_001012732.1   flanking_3UTR            −238854

10.1371/journal.pone.0007765.t004

###### Top 23 significant SNPs within or close to 9 pathway genes associated with AraC IC~50~ values (p\<0.05).
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  SNP           r-value   p-value   q-value    N     MAF    Chr   Position    Genome Build   Gene Symbol        Gene          Location      Location Relative To Gene
  ------------ --------- --------- --------- ----- ------- ----- ----------- -------------- ------------- ---------------- --------------- ---------------------------
  rs9472236      0.240     0.003    0.99971   173   0.225    6    44314728        36.1         SLC29A1      NM_004955.1     flanking_3UTR             −4872
  rs2037067      0.222     0.006    0.99971   172   0.471    4    183810578       36.1          DCTD       NM_001012732.1   flanking_3UTR            −237660
  rs11999726    −0.219     0.006    0.99971   173   0.073    9    86104976        36.1         SLC28A3      NM_022127.1        intron                 −516
  rs7830150     −0.213     0.008    0.99971   173   0.187    8    103162269       36.1          RRM2B       NM_015713.3     flanking_3UTR            −123638
  rs1614627     −0.196     0.015    0.99971   173   0.17     1    20819343        36.1           CDA        NM_001785.1     flanking_3UTR             −1360
  rs2224211      0.192     0.017    0.99971   173   0.196    6    85619788        36.1          NT5E        NM_002526.1     flanking_5UTR            −596740
  rs7874528     −0.183     0.023    0.99971   173   0.17     9    86020319        36.1         SLC28A3      NM_022127.1     flanking_3UTR            −62593
  rs17414857    −0.182     0.023    0.99971   173   0.094    8    103139477       36.1          RRM2B       NM_015713.3     flanking_3UTR            −146430
  rs4877839     −0.182     0.024    0.99971   173   0.12     9    86118829        36.1         SLC28A3      NM_022127.1        intron                 −640
  rs17343066     0.181     0.024    0.99971   173   0.36     9    86135893        36.1         SLC28A3      NM_022127.1        intron                 −9416
  rs12526113    −0.181     0.024    0.99971   173   0.33     6    85612351        36.1          NT5E        NM_002526.1     flanking_5UTR            −604177
  rs2324753     −0.181     0.024    0.99971   173   0.33     6    85615181        36.1          NT5E        NM_002526.1     flanking_5UTR            −601347
  rs12554292    −0.180     0.025    0.99971   173   0.135    9    86256385        36.1         SLC28A3      NM_022127.1     flanking_5UTR            −83152
  rs1570311     −0.175     0.029    0.99971   173   0.161    6    86211870        36.1          NT5E        NM_002526.1     flanking_5UTR             −4658
  rs4487548     −0.175     0.029    0.99971   173   0.161    6    86199130        36.1          NT5E        NM_002526.1     flanking_5UTR            −17398
  rs9344525     −0.175     0.029    0.99971   173   0.161    6    86208157        36.1          NT5E        NM_002526.1     flanking_5UTR             −8371
  rs6850978      0.171     0.034    0.99971   173   0.424    4    183809384       36.1          DCTD       NM_001012732.1   flanking_3UTR            −238854
  rs9450270     −0.170     0.034    0.99971   173   0.187    6    86171485        36.1          NT5E        NM_002526.1     flanking_5UTR            −45043
  rs3743162      0.170     0.034    0.99971   173   0.129   15    83231973        36.1         SLC28A1      NM_201651.1        intron                  −7
  rs1265138      0.165     0.042    0.99971   171   0.148    8    103269212       36.1          RRM2B       NM_015713.3     flanking_3UTR            −16695
  rs1569040      0.163     0.043    0.99971   172   0.147   17    17246812        36.1          NT5M        NM_020201.3     flanking_3UTR            −55110
  rs12500335    −0.162     0.044    0.99971   172   0.091    4    183944775       36.1          DCTD       NM_001012732.1   flanking_3UTR            −103463
  rs11598702    −0.163     0.045    0.99971   171   0.246   10    104887975       36.1          NT5C2       NM_012229.2        intron                 −1178

10.1371/journal.pone.0007765.t005

###### 24 candidate SNPs with cis-regulation of pathway genes (p\<0.0001).
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  SNP             Probeset      r-value (SNP vs Exp)   p-value (SNP vs Exp)      SNP        MAF    Chr   Position    Genome Build   Gene Symbol        Gene          Location      Location Relative to Gene
  ------------ --------------- ---------------------- ---------------------- ------------ ------- ----- ----------- -------------- ------------- ---------------- --------------- ---------------------------
  rs1319763       225044_at            0.6435                7.54E-33         rs1319763    0.22    17    37245316        36.1         NT5C3L       NM_052935.2        intron                 −266
  rs1046403       225044_at            0.6420                1.54E-32         rs1046403    0.219   17    37237346        36.1         NT5C3L       NM_052935.2        coding              \[142/58\]
  rs4796712       225044_at            0.3728                2.69E-10         rs4796712    0.099   17    37240656        36.1         NT5C3L       NM_052935.2        coding               \[77/12\]
  rs9344525       227486_at           −0.3034                3.91E-07         rs9344525    0.167    6    86208157        36.1          NT5E        NM_002526.1     flanking_5UTR             −8371
  rs1570311       227486_at           −0.3034                3.91E-07         rs1570311    0.167    6    86211870        36.1          NT5E        NM_002526.1     flanking_5UTR             −4658
  rs4487548       227486_at           −0.3034                3.91E-07         rs4487548    0.167    6    86199130        36.1          NT5E        NM_002526.1     flanking_5UTR            −17398
  rs9344525       203939_at           −0.2821                2.59E-06         rs9344525    0.167    6    86208157        36.1          NT5E        NM_002526.1     flanking_5UTR             −8371
  rs1570311       203939_at           −0.2821                2.59E-06         rs1570311    0.167    6    86211870        36.1          NT5E        NM_002526.1     flanking_5UTR             −4658
  rs4487548       203939_at           −0.2821                2.59E-06         rs4487548    0.167    6    86199130        36.1          NT5E        NM_002526.1     flanking_5UTR            −17398
  rs7277        201572_x\_at          −0.2768                4.20E-06           rs7277     0.341    4    184048507       36.1          DCTD       NM_001012732.1       3UTR              \[269/1038\]
  rs9344525     1553995_a\_at         −0.2709                6.56E-06         rs9344525    0.167    6    86208157        36.1          NT5E        NM_002526.1     flanking_5UTR             −8371
  rs1570311     1553995_a\_at         −0.2709                6.56E-06         rs1570311    0.167    6    86211870        36.1          NT5E        NM_002526.1     flanking_5UTR             −4658
  rs4487548     1553995_a\_at         −0.2709                6.56E-06         rs4487548    0.167    6    86199130        36.1          NT5E        NM_002526.1     flanking_5UTR            −17398
  rs4910907     201477_s\_at          −0.2705                6.81E-06         rs4910907    0.167   11     4125427        36.1          RRM1        NM_001033.2     flanking_3UTR             −8745
  rs9907244       225044_at           −0.2650                1.05E-05         rs9907244    0.455   17    37234426        36.1         NT5C3L       NM_052935.2     flanking_3UTR             −558
  rs9344525      1553994_at           −0.2621                1.33E-05         rs9344525    0.167    6    86208157        36.1          NT5E        NM_002526.1     flanking_5UTR             −8371
  rs1570311      1553994_at           −0.2621                1.33E-05         rs1570311    0.167    6    86211870        36.1          NT5E        NM_002526.1     flanking_5UTR             −4658
  rs4487548      1553994_at           −0.2621                1.33E-05         rs4487548    0.167    6    86199130        36.1          NT5E        NM_002526.1     flanking_5UTR            −17398
  rs2250159       203302_at           −0.2613                1.46E-05         rs2250159    0.369    9    85966866        36.1         SLC28A3      NM_022127.1     flanking_3UTR            −116046
  rs1474500     201477_s\_at          −0.2561                2.11E-05         rs1474500    0.166   11     4080688        36.1          RRM1        NM_001033.2        intron                 −801
  rs12990630    1553540_a\_at         −0.2518                2.94E-05         rs12990630   0.082    2    18973412        36.1         NT5C1B      NM_001002006.1   flanking_5UTR            −339093
  rs4910896     201477_s\_at          −0.2492                3.58E-05         rs4910896    0.172   11     4118132        36.1          RRM1        NM_001033.2     flanking_3UTR             −1450
  rs16845804      236703_at            0.2410                6.54E-05         rs16845804   0.221    4    72208285        36.1           DCK        NM_000788.1     flanking_3UTR            −92808
  rs17271644    201572_x\_at          −0.2376                8.30E-05         rs17271644   0.495    4    184046266       36.1          DCTD       NM_001012732.1   flanking_3UTR             −1972

Functional Characterization of Candidate Genes {#s2e}
----------------------------------------------

Our association studies were performed with human lymphoblastoid cell lines but the gene regulation is tissue specific [@pone.0007765-Dimas1]. Therefore, to investigate the impact of the SNPs that we had identified on gene expression and on gemcitabine and AraC cytotoxicity and to functionally validate our association results, we also studied tumor cell lines, in this case, two pancreatic cancer cell lines, to validate our association results. We performed siRNA knock down for three SNP-associated genes, including *VAV3*, *MGMT* that are associated with the SNP in *IQGAP2* and *GPM6A* which is associated with the SNP in *TGM3*, to determine whether genes that had expression associated with the two SNPs might influence drug IC~50~. We selected *VAV3* and *GPM6A* because each of these genes had two probesets associated with rs3797418 and rs6082527, respectively. VAV3 was also highly associated with gemcitabine and AraC IC~50~ while GPM6A gene expression was associated with gemcitabine IC~50~ ([**Figure 4A and 4B**](#pone-0007765-g004){ref-type="fig"}). As with *TGM3*, we also performed knock down of *GPM6A* for AraC. However, the association was most significant in the CA group, which could be due to differences in allele frequencies among the three ethnic groups studied. Expression of the third gene, *MGMT*, was also associated with both SNPs (rs3797418 with p = 1.22×10^−7^ and rs6082527 with p = 8.06×10^−8^) and with gemcitabine and AraC IC~50~ values (p = 5.49×10^−8^ and 1.85×10^−4^, respectively). We also included *IQGAP2* and *TGM3* in the siRNA knock down studies to determine whether the genes harboring these two SNPs might themselves have functional effects on gemcitabine or AraC cytotoxicity. Finally, we included a positive control siRNA, FKBP5, a gene that we had previously shown to be important for gemcitabine response [@pone.0007765-Li1].

![Association among SNPs in *IQGAP2* and *TGM3* with expression and gemcitabine or AraC cytotoxicity.\
(A) SNP rs3797418 (A/C) association with VAV3 expression, gemcitabine IC~50~ values and VAV3 expression association with gemcitabine IC~50~ in individual ethnic groups and all of the cell lines. (B) SNP rs6082527 (A/G) association with GPM6A gene expression, gemcitabine IC~50~ values and GPM6A gene expression association with gemcitabine IC~50~ values. (C). SNP rs3797418 (A/C) association with VAV3 expression, AraC IC~50~ values and VAV3 expression association with AraC IC~50~ in individual ethnic groups and all of the cell lines. Each dot represents one sample. Genotypes for each SNP are plotted against gene expression levels (upper panels) as well as gemcitabine or AraC IC~50~ values (middle panels). In the lower panel, correlations were determined between gene expression levels and gemcitabine or AraC IC~50~ values.](pone.0007765.g004){#pone-0007765-g004}

Specific and negative control siRNAs were transiently transfected into human SU86 or Hup-T3 pancreatic cancer cell lines, cell lines selected on the basis of endogenous expression level of genes of interest, followed by gemcitabine or AraC cytotoxicity assays. We selected pancreatic cancer cell lines because gemcitabine is the standard of care for the therapy of pancreatic cancer. Down regulation of VAV3 in SU86 cells significantly desensitized the cells to gemcitabine and AraC ([**Figure 5A**](#pone-0007765-g005){ref-type="fig"}), consistent with the result of the association study (gemcitabine p = 9.14E-10 and AraC p = 1.24E-11). Down regulation of GPM6A in HupT3 cell line also resulted in desensitization to gemcitabine (p = 1.35E-07), an observation consistent with our association study results for GPM6A gene expression and gemcitabine IC~50~ ([**Figure 5B**](#pone-0007765-g005){ref-type="fig"}). Interestingly, although GPM6A expression was not significantly associated with AraC response, the knock down experiments showed a similar effect for AraC (p = 3.66E-12) ([**Figure 5B**](#pone-0007765-g005){ref-type="fig"}). We also performed similar experiments of knock down of these two genes using selected lymphoblastoid cell lines and it showed similar results as in the tumor cell lines ([**Figure 5A** right panel](#pone-0007765-g005){ref-type="fig"}, AraC p = 0.0074, gemcitabine p = 0.0085; [**Figure 5B** right panel](#pone-0007765-g005){ref-type="fig"}, AraC p = 0.001, gemcitabine p = 0.002). However, down-regulation of MGMT did not alter either gemcitabine or AraC cytotoxicity. Furthermore, knock down of IQGAP2 and TGM3 themselves, did not have significant effect on gemcitabine or AraC cytotoxicity, an observation indicating that the genes harboring these two SNPs might not have a direct effect on cytotoxicity for the two drugs, and that rs3797418 and rs6082527 might just be markers for gemcitabine and/or AraC cytotoxicity.

![Functional characterization of candidate genes with siRNA knock down of VAV3 (A) and GPM6A (B).\
Knock down of VAV3 and GPM6A expression in human SU86 and Hup-T3 pancreatic cancer cell lines as well as lymphoblastoid cell lines showed increased resistance to gemcitabine and AraC after siRNA knock down as determined by MTS assays. Error bars represent SEM values for 3 independent experiments. Quantitative RT-PCR was performed to assess VAV3 and GPM6A gene expression levels after knock down with specific siRNAs. Results are expressed as % of control. Error bars represent SEM values for 3 independent experiments. \*  = p\<0.05.](pone.0007765.g005){#pone-0007765-g005}

Characterization of SNPs in *IQGAP2* and *TGM3* {#s2f}
-----------------------------------------------

In order to further characterize the two SNPs (rs3797418 and rs6082527) in *IQGAP2* and *TGM3*, we also performed genotype-phenotype correlation studies with the expression of these two genes, i.e., we determined the possible cis-association of the SNPs with IQGAP2 and TGM3 expression. However, neither SNP was associated with the expression of either IQGAP2 or TGM3, indirectly supporting the results of the *IQGAP2* and *TGM3* knock down experiments. We then determined LD patterns for 500 kb regions around each of the two SNPs using the HapMap data for each ethnic group. As shown in [**Figure 6**](#pone-0007765-g006){ref-type="fig"}. LD patterns surrounding the two SNPs differed among the three ethnic groups. No SNPs within the 500 kb region around rs3797418 were in high LD with rs3797418. One SNP, rs6047696 in an intergenic region, was in moderate LD with rs6082527 in the CEPH population (r^2^ = 0.682, D′ = 0.826). In addition, rs12479538, located in an intron of *STK35*, a serine/threonine kinase 35, was in complete linkage disequilibrium with rs6082527 in the Han Chinese population (r^2^ = 1, D′ = 1). The p-value for the association between the rs6082527 SNP and gemcitabine IC~50~ was 0.006, which was not significant after correction for multiple comparisons. Unfortunately, the rs12479538 SNP was not on the 550K SNP array. Obviously, the association of the two SNPs in *IQGAP2* and *TGM3* with gemcitabine or AraC response and with the expression of other genes might result from the effects of either known or unknown polymorphisms in tight linkage disequilibrium with these two SNPs.

![Linkage disequilibrium within ∼300 Kb surrounding the rs3797418 and rs6082527 SNPs.\
Red indicates combinations where D′ = 1 and linkage of disequilibrium (LOD) ≥2; light red, combinations where D′\<1 and LOD ≥2; red squares, combinations where D′ = 1 and LOD \<2; white squares, combinations with D′\<1 and LOD \<2. SNPs are arranged in order from 5′ to 3′ in each gene, as shown in the gene structure above each plot.](pone.0007765.g006){#pone-0007765-g006}

Since these two SNPs, rs3797418 (A/C) and rs6082527 (A/G), were located in the intron of *IQGAP2* and the 5′-FR of *TGM3*, respectively, we determined the relationship among genes associated with these two SNPs. Ingenuity Pathway analysis was performed by mapping the 10 and 8 unique genes that were significantly associated with rs3797418 in *IQGAP2* for gemcitabine and AraC, respectively. Results of the Ingenuity Pathway Analysis showed a network that connected all of the 10 genes centered on ERK and TNF for gemcitabine and all of the 8 genes centered on TNF, ERK, TP53 for AraC (**[Figure S1](#pone.0007765.s007){ref-type="supplementary-material"}**). However, since only 5 genes were identified to be associated with rs6082527 through our analysis, no network was identified when we analyzed genes that were associated with this SNP.

Discussion {#s3}
==========

Variation in response to chemotherapeutic agents is a common phenomenon in the clinic. Many factors can contribute to this variation. However, genetic variation is one of the major factors that play an important role in determining response to drugs. Therefore, it is important to identify SNPs that might be used as predictive markers for drug response. In a previous study, we identified candidate genes for which variation in expression levels were associated with variation in response to gemcitabine and AraC using a lymphoblastoid cell line model system [@pone.0007765-Li1]. In the current set of experiments, we expanded our study to include genome-wide SNPs to test the hypothesis that SNPs across the genome might contribute significantly to variation in response to two cytidine analogues, gemcitabine and AraC. Lymphoblastoid cell lines with genome-wide SNP and expression data have been used successfully to identify pharmacogenomic candidates associated with response to other chemotherapeutic agents [@pone.0007765-Huang1], [@pone.0007765-Baum1]. The advantage of using this cell-based model system is that we have obtained different types of high throughput genomic and transcriptomic data, which makes it possible to test the hypothesis that genetic variation might contribute to variation in drug response, in this case, two cytidine analogues [@pone.0007765-Kern1], [@pone.0007765-Kindler1], [@pone.0007765-Hertel1], [@pone.0007765-Lokiec1]. Many previous pharmacogenetic studies for these two drugs were focused on the gemcitabine bioactivation and metabolism pathway [@pone.0007765-Kim1], [@pone.0007765-Kim2]. For example, SNPs identified in genes encoding ribonucleotide reductase (RRM1) and cytidine deaminase (CDA) were found to be associated with gemcitabine chemosensitivity in the NCI60 cell lines or with active gemcitabine plasma metabolites levels [@pone.0007765-Kwon1]--[@pone.0007765-Sugiyama1]. Those findings provided the initial evidence that genetic variation might contribute to the variation in cytidine analogue response.

In the present study, we performed a genome-wide association study with 171 lymphoblastoid cell lines for which we obtained genome-wide SNPs by use of Illumina 550K SNP chips, as well as, expression array data obtained with Affymetrix U133 Plus 2.0 GeneChips. Those data made it possible for us to take a comprehensive approach in which we combined genotype, expression and cytotoxicity data for the two cytidine analogues ([**Figure 3**](#pone-0007765-g003){ref-type="fig"}) to identify SNPs that might contribute to drug sensitivity through their impact on the regulation of gene expression ([**Tables 1**](#pone-0007765-t001){ref-type="table"} and [**2**](#pone-0007765-t002){ref-type="table"}). However, there were only 49 SNPs among the top significant SNPs for gemcitabine and AraC that were common for both drugs, indicating even though the two drugs share common mechanisms and the same metabolic pathway, there are differences between these two drugs. This stepwise analysis helped us to narrow our focus to two SNPs associated with both expression and drug cytotoxicity. Those two SNPs, rs3797418 and rs6082527, were located, respectively, in an intron of *IQGAP2* and the 5′-FR of *TGM3*. To further understand the biology responsible for the association of rs3797418 and rs6082527 with gene expression and drug cytotoxicity, we performed knock down of selected genes with expression that was associated with these two SNPs. Knock down of VAV3 and GPM6A in pancreatic cancer cell lines desensitized the cells to gemcitabine and AraC ([**Figure 5A and 5B**](#pone-0007765-g005){ref-type="fig"}). VAV3 is a member of the VAV family that has guanine nucleotide exchange activity toward small GTP-binding proteins. VAV3 is a known proto-oncogene that can be involved in tumorgenesis [@pone.0007765-Hornstein1]--[@pone.0007765-Turner1]. As shown in our network analysis (**[Figure S1](#pone.0007765.s007){ref-type="supplementary-material"}**), VAV3 can be involved in multiple signaling pathways. Although the mechanism responsible for VAV3 involvement in gemcitabine and AraC response is unclear, given the multiple roles of VAV3 in cancer development, it was not surprising that this gene might contribute to variation in response to chemotherapeutic agents. GPM6A, also known as M6a, is a transmembrane glycoprotein that belongs to the myelin protolipid protein (PLP) family. This gene is expressed mainly in nervous system, and recent studies have suggested the importance of GPM6A in processes involved in neural development such as neurite extension, survival and differentiation [@pone.0007765-Lagenaur1]--[@pone.0007765-Alfonso1]. GPM6A also interacts with a number of G protein coupled receptors and downstream signaling pathways [@pone.0007765-Wu2]. One recent report suggested that GPM6A might function as a chaperone in cancer cells as part of global profiling of the cell surface proteome for cancer cells [@pone.0007765-Shin1]. Although there is limited information with regard to the involvement of this gene in tumorgenesis and drug resistance, our results suggest a possible role for *GPM6A* in response to cytidine analogue antineoplastic agents.

Although the two SNPs in *IQGAP2* and *TGM3* that we studied were associated with multiple downstream genes with expression that was also associated with gemcitabine or AraC cytotoxicity, we did not identify an association between these two SNPs and either IQGAP2 and TGM3 gene expression, nor did we observe an influence of IQGAP2 and TGM3 on gemcitabine or AraC cytotoxicity after knock down of these two genes.

*IQGAP2* is approximately 300 kb and *TGM3* is about 45 kb in length. [**Figure 6**](#pone-0007765-g006){ref-type="fig"} shows the haplotype structure within ∼300 kb surrounding the rs3797418 and rs6082527 SNPs. Linkage analysis was also performed with HapMap data sets in different ethnic groups. However, one of the SNPs linked to rs6082527 was not associated with gemcitabine IC~50~, and the other was not present on the 550K SNP array. Therefore, the effect of the two SNPs in *IQGAP2* and *TGM3* on drug response and other gene expression might result from the effects of either known or unknown polymorphisms linked to those two SNPs.

In summary, we have used a data-rich cell-based model system to perform association studies of gemcitabine and AraC cytotoxicity with genome-wide SNP and expression array data. Use of this approach enabled us to identify SNPs that might be markers for cytidine analogue sensitivity and genes that might play an important role in variation in response to these drugs. There are also limitations associated with the use of these cell lines, as described by Choy et. al [@pone.0007765-Choy1]. The potential confounding factors besides genetic effect could include cell growth rate, EBV transformation and ATP condition. However, that same paper stated that "RNA levels are predominantly correlated to inter-individual differences in EC50. Much less of the correlation between RNA and EC50s reflects intra-individual variation". That conclusion supports the hypothesis that inter-individual variation in RNA levels due to genetic variation may contribute to variation in drug response phenotype. One limitation of the use of these cell lines is the possibility that EBV transformation might influence drug sensitivity and/or expression profiles, so we might miss some genes of importance for the drug response phenotype, either because they are not expressed in these cell lines or, after transformation, are down-regulated. There is also evidence that gemcitabine and doxorubicin can induce the lytic form of EBV transformed cells [@pone.0007765-Feng1], [@pone.0007765-Feng2]. However, we and other groups have demonstrated success with the use of this type of cell line in previous pharmacogenomic studies [@pone.0007765-Li1], [@pone.0007765-Huang1], [@pone.0007765-Huang2], and functional characterization of the genes identified during the present study supports the feasibility of this approach. The results of the present study enhance our understanding of the role of genetic variation in variation in gemcitabine and AraC sensitivity and resistance and may help to identify mechanisms involved in the actions of these drugs. In addition, these SNPs and genes can now potentially be tested in the clinical setting and, if confirmed, they could significantly enhance our ability to individualize treatment with these two drugs.

Materials and Methods {#s4}
=====================

Cell Line {#s4a}
---------

174 lymphoblastoid cell lines from 60 Caucasian-American (CA), 54 African-American (AA) and 60 Han Chinese-American (HCA) (sample sets HD100CAU, HD100AA, and HD100CHI) subjects were purchased from the Coriell Cell Repository (Camden, NJ). All of these cell lines had been obtained and anonymized by the National Institute of General Medical Sciences prior to deposit, and all subjects had provided written consent for the use of their DNA and cells for experimental purposes. Human SU86 and Hup-T3 pancreatic cancer cell lines were gifts from Dr. Daniel D. Billadeau, Mayo Clinic.

siRNA {#s4b}
-----

The siRNA duplexes used in the knock down studies were purchased from the QIAGEN Inc. (Valencia, CA).

Drugs and Cell Proliferation Assays {#s4c}
-----------------------------------

Gemcitabine was provided by Eli Lilly (Indianapolis, IN). AraC was purchased from Sigma-Aldrich (St. Louis, MO). Cytotoxicity assays with the lymphoblastoid cell and tumor cell lines were performed with the CellTiter 96® AQ~ueous~ Non-Radioactive Cell Proliferation Assay (Promega Corporation, Madison, WI) as previously described [@pone.0007765-Li1]. Estimation of the IC~50~ phenotype (effective dose that kills 50% of the cells) was calculated using a four parameter logistic model. Of the 174 cell lines, cytotoxicity curves for two cell lines were removed from further analysis due to possible experimental error.

Gene Expression {#s4d}
---------------

Expression array data were obtained for all 174 lymphoblastoid cell lines as previously described [@pone.0007765-Li1]. Specifically, biotin-labeled cRNA, produced by *in vitro* transcription, was hybridized to Affymetrix Human Genome U133 Plus 2.0 GeneChips. Each of these GeneChip contains 54,613 probesets. Normalization of the expression array data was performed using GCRMA [@pone.0007765-Bolstad1], [@pone.0007765-Wu3].

Genome-Wide SNP Analysis {#s4e}
------------------------

Illumina HumanHap 550K BeadChips were used to obtain genome-wide SNP data for all 174 cell lines. Specifically, each DNA sample was genotyped using the Illumina version 3 BeadChip, which assays 561,278 single nucleotide polymorphisms (SNPs). All genotyping was conducted at the Genotype Shared Resource (GSR) at the Mayo Clinic, Rochester, MN. SNPs with call rates \<0.95 were excluded, as were DNA samples with call rates \<0.95. The call rate for rs3797418 and rs6082527 SNPs were 100% for all cell lines. One African American sample was removed due to a call rate \<0.95, resulting in 173 cell lines with genotypic data and 171 cell lines with both genotypic data and phenotypic data (gemcitabine IC~50~ values)

Transient Transfection and RNA Interference {#s4f}
-------------------------------------------

Human SU86 and HupT3 pancreatic cancer cell lines were used to perform the siRNA studies. The Hiperfect transfection reagent (QIAGEN) was used for siRNA reverse transfection. Specifically, cells were seeded into 96-well plates and were mixed with siRNA-complex, consisting of 5 nM of specific or negative control siRNA (QIAGEN), and the Hiperfect transfection reagent. The lymphoblastoid cell lines were transfected with control siRNA and specific siRNA for GPM6A and VAV3 using the electroporation (Nucleofector® Lonza Walkersville Inc., Walkersville, MD). Specifically, 1.25×10^6^ cells suspended in Cell Line Nucleofector Solution V (Lonza Walkersville Inc.) were mixed with 2 µM control or specific siRNA before the electroporation.

Quantitative Real-Time Reverse Transcription-PCR {#s4g}
------------------------------------------------

Total RNA was isolated from cultured cells with the Qiagen RNeasy kit (QIAGEN Inc. Valencia, CA), followed by QRT-PCR performed with the 1-step, Brilliant SYBR Green QRT-PCR master mix kit (Stratagene, La Jolla, CA). Specifically, primers purchased from Qiagen were used to perform QRT-PCR using the Stratagene Mx3005P™ Real-Time PCR detection system (Stratagene). All experiments were performed in triplicate with β-actin as an internal control. Reverse transcribed Universal Human reference RNA (Stratagene) was used to generate a standard curve. Control reactions lacked RNA template.

Statistical Methods {#s4h}
-------------------

Quality control for the Illumina genotypes was performed before performing the association study. SNPs that deviated from HWE (minimum exact test for HWE [@pone.0007765-Guo1], [@pone.0007765-Wigginton1] and stratified test for HWE [@pone.0007765-Schaid1] p-values \<0.001), with call rates \<95% or SNPs with MAFs \<5% were removed from the analysis. Subjects with call rates \<95% were also removed from all SNP analyses. No effects for SNPs were seen with the Illumina platforms. The plot for the most significant SNPs are shown in **[Figure S2](#pone.0007765.s008){ref-type="supplementary-material"}**. Next, population stratification was assessed. Because we studied cell lines chosen to represent common human genetic diversity, multiple races/ethnic groups were represented in the lymphoblastoid cell lines. Therefore, we used the method developed by Price et al. [@pone.0007765-Price1] to adjust for population stratification. This method uses an eigen analysis to detect and adjust for population stratification. Within each race, eigen analysis was completed, with the top five eigenvectors saved. Using the five eigenvectors within each race, individual genotypes were adjusted using the model with representing the genotype for the i^th^ cell line in racial group *j* (*j* = 1, 2, 3), the race effect for race *j*, and the *k* ^th^ eigenvector, *k* = 1, 5, effect for race *j*. Similarly, the log transformed IC~50~ values, were also adjusted for race using the five eigenvectors, in addition to gender. Pearson correlation coefficients were then computed using the adjusted genotypes and IC~50~ variables. False Discovery q-values [@pone.0007765-Storey1], [@pone.0007765-Storey2] were also computed for each test. Similar sets of analyses were also performed for the association of IC~50~ with mRNA expression and SNPs with mRNA expression. Pairwise LD was estimated using r-squared statistics and were displayed graphically using the Haploview software [@pone.0007765-Barrett1].

Integrative Genomic Analysis {#s4i}
----------------------------

To integrate genotype, expression and drug cytotoxicity data, we used an approach similar to "genomic convergence" [@pone.0007765-Hauser1]--[@pone.0007765-Schadt1], as depicted graphically in [**Figure 2**](#pone-0007765-g002){ref-type="fig"}. We used a less stringent cut off for p-values used to identify the initial set of SNPs that were associated with IC~50~ to avoid missing possible candidates with biological significance. First, we identify SNPs associated with IC~50~ (p-values \<0.001). One of the functional mechanisms by which SNPs might influence cytotoxicity is by regulating transcription in either a cis (SNP within or near the gene) or trans- (SNP not within or near the gene) manner. Therefore, we determined the expression probesets that were associated with these identified SNPs (p-values \<10^−6^). Next, to determine whether the expression probesets associated with these SNPs were also associated with IC~50~ values for gemcitabine and AraC, we correlated these expression probesets with IC~50~ for both drugs with a p\<0.001. A set of genes was then selected to test functionally for their possible biological relevance with regard to drug response.

Bioinformatics Pathway Analysis {#s4j}
-------------------------------

To further understand biological interactions between the downstream genes, pathway analysis was performed on genes that had significant associations with the two SNPs and with phenotype. In the case of gemcitabine, SNP rs3797418 present in the intronic region of *IQGAP2* showed significant associations with 14 probesets during the SNP-expression analysis; and these same 14 probesets also had significant correlations with IC~50~ phenotype. Therefore, these14 probesets that mapped to 10 unique genes were used to perform pathway analysis. A similar analysis was performed with AraC using the 8 genes that were significantly associated with the SNP rs3797418 to perform the pathway analysis. SNP rs6082527 close to *TGM3* gene was associated with 6 probesets that showed significant correlations with IC~50~ phenotype. Therefore, pathway analysis was also performed for the 6 probesets that mapped to 5 genes to identify major pathways that might be involved with the downstream effects of this SNP. Ingenuity software was used to perform the pathway analysis. This software consists of a curated database and several analysis tools to obtain pathways associated with a set of genes. Ingenuity calculates p-value for the probability of finding a set of genes within a given pathway. Fisher\'s exact test is used to calculate the p-values.
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======================

###### 

Top polymorphism associated with gemcitabine cytotoxicity (IC50 values). 492 significant SNPs were associated with gemcitabine IC50 values with p-values \<0.001.
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Top candidates for association between 550K genome-wide SNPs and AraC cytotoxicity. 553 significant SNPs were associated with AraC IC50 values with p-values \<0.001.
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Top SNPs that were significantly associated with both gemcitabine and AraC (p\<0.001).
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Top candidates for association between 492 SNPs and whole gene expression array data (54,000 probe sets). 100 SNPs among 492 located within or close to 78 genes were associated with 296 expression probe sets (220 unique genes) with p-values \<10−6.
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Top candidates for association between 553 SNPs and whole gene expression data (54,000 probesets). 140 SNPs among 553 SNPs located within or close to 843 probe sets (563 unique genes) with p-values \<10−6.
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Genes within the gemcitabine/AraC transport, metabolism and target pathway.
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Network analysis. Genes that were associated with rs3797418, an intron SNP in IQGAP2, were used to perform network analysis using Ingenuity Pathway Analysis. Dotted line indicates an indirect connection and solid lines indicate a direction interaction between genes.
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Illumina intensity plot for top candidate SNPs.
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